RecruitingNot ApplicableNCT06609200

Electro-Acupuncture for Obese Patients With Insulin Resistance

Electro-acupuncture for the Obese Patient With Insulin Resistance: a Randomized Sham-controlled Clinical Trial

Sponsor

Nanyang Technological University

Enrollment

60 participants

Start Date

Oct 10, 2024

Study Type

INTERVENTIONAL

Conditions

Obesity Insulin Resistance

Summary

This clinical trial aims to evaluate the efficacy and safety of electro-acupuncture for obese patients with insulin resistance. 60 participants will be randomized and allocated to either the electro-acupuncture arm or the sham acupuncture arm.

Eligibility

Min Age: 21 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Acupuncture needles for people with insulin resistance and obesity. The study is currently recruiting participants at 1 location. People eligible for this study include aged 21 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEAcupuncture needles

The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore.

Locations(1)

Nanyang Technological University Traditional Chinese Medicine Clinic

Singapore, Singapore

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06609200

Related Trials

Evaluation of the Care Pathway Offered by the "Chronic Disease Unit" to Obese Patients

NCT065382201 location

A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body

NCT074073481 location

A Study of LY3971297 in Healthy Participants

NCT061482727 locations

Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)

NCT072258161 location

Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity

NCT0749788023 locations